This site is intended for UK healthcare professionals only

NEWS

 

Keep up to date with the latest news on bladder health, management and treatment.

Have you got a story to share? Email the team today.

Patient holding their bladder in relation to the article: Urinary Incontinence Therapy
22 December 2021
Urinary Incontinence
Urinary Incontinence Therapy

1 in 3 women suffers from stress urinary incontinence (SUI) at some point in their lives. SUI tends to develop as women get older, often during or after pregnancy. The leaks are due to a weakness in the pelvic floor that can allow urine to leak out during normal daily activities such as coughing, laughing, exercising, or lifting an object.

Bulkamid, a soft, water-based gel delivered via a series of small injections into the urethral wall is an FDA-approved treatment for SUI. Similar to some facial fillers, Bulkamid remains in the body over time without causing reactions in the surrounding tissue, resulting in durable, long-lasting relief that some experts in urogynecology are calling game-changing.

Northwest Specialty Hospital’s women’s health service, Northwest Women’s Care, is the first hospital in the Inland Northwest to offer this innovative new therapy. The FDA-approved treatment takes only 15 minutes to complete in the office, requires no incisions, and has demonstrated long-lasting symptom relief.

Dr. Adam Duke, the medical director of Northwest Women’s Care, commented “Bulkamid offers our patients at Northwest Women’s Care an exciting alternative to the urinary incontinence surgery. We believe that this treatment will not only be more convenient for many of our patients but also provide sustained relief from their symptoms.”

Read the full article online.

Read more news from The Bladder Interest Group now.

Latest News

Luja™ shows significant improvement in bladder emptying

Study results show that Coloplast’s new intermittent male catheter with 80+ micro-holes, Luja, achieved complete bladder emptying in one free flow* in 90% of catheterisations. Coloplast has finalised its first pivotal clinical study on Luja, a new intermittent male...

Artificial Intelligence used in bladder cancer treatment assessment

A computerised artificial intelligence (AI)-based decision support system (CDSS-T) enhanced the performance of clinicians when assessing patients’ response to chemotherapy prior to radical cystectomy, according to results from a small multi-institutional observer...

New treatment for urothelial cancer approved by NICE

Over 800 people with locally advanced or metastatic urothelial cancer are set to benefit from a new treatment for urothelial cancer – avelumab – following its recommendation for routine NHS funding in final draft guidance published NICE. The recommendation for this...